Provided herein are devices and methods suitable for sequencing, amplifying, analyzing, and performing sample preparation procedures for nucleic acids and other biomolecules.

A biosensor device controls actuation of label particles e.g., using frustrated total internal reflection. By applying a predetermined actuation force on the label particles and determining the effect of the applied actuation force in a binding volume or surface of a sensor cartridge of the biosensor device, a feedback control of the actuation force is applied.

A method of monitoring a substance in a well can include disposing at least one optical electromagnetic sensor and at least one electromagnetic transmitter in the well, and inducing strain in the sensor, the strain being indicative of an electromagnetic parameter of the substance in an annulus between a casing and a wellbore of the well. A system for monitoring a substance in a well can include at least one electromagnetic transmitter, and at least one optical electromagnetic sensor with an optical waveguide extending along a wellbore to a remote location, the sensor being positioned external to a casing in the wellbore.

A cartridge assembly, and method of using the same, is provided. The assembly includes a sample processing card and a substrate attached thereto. The card has an injection port for receiving a test sample; at least one metering chamber; a mixing material source for introducing mixing material(s) to the metering chamber; fluid communication channels fluidly connecting the injection port and the mixing material source to the metering chamber; and at least one output port for delivering the test sample to a sensor (e.g., GMR sensor). The substrate has associated therewith: the sensor for sensing analytes in the test sample; electrical contact portions for an electrical connection with a reader unit; and a memory chip. The assembly further includes a pneumatic interface with port(s) and corresponding communication channel(s) fluidly connected to card. The interface connects with an off-board pneumatic system and enables application of positive and negative pressurized fluid to the card to move the test sample and one or more mixing materials therein and to the sensor.

A cartridge assembly, and method of using the same, is provided. The assembly includes a sample processing card and a substrate attached thereto. The card has an injection port for receiving a test sample; at least one metering chamber; a mixing material source for introducing mixing material(s) to the metering chamber; fluid communication channels fluidly connecting the injection port and the mixing material source to the metering chamber; and at least one output port for delivering the test sample to a sensor (e.g., GMR sensor). The substrate has associated therewith: the sensor for sensing analytes in the test sample; electrical contact portions for an electrical connection with a reader unit; and a memory chip. The assembly further includes a pneumatic interface with port(s) and corresponding communication channel(s) fluidly connected to card. The interface connects with an off-board pneumatic system and enables application of positive and negative pressurized fluid to the card to move the test sample and one or more mixing materials therein and to the sensor.

A breathing monitor that includes a contactless sensor that uses magneto-LC resonance technology is provided. The breathing monitor collects breathing data from a patient that indicates a breathing pattern of the patient. A model trained using machine learning using breathing patterns collected from patients known to have different stages of COVID-19 is used to process the collected breathing data and to determine whether the patient has COVID-19. The model further determines the stage of COVID-19. The breathing monitor can identify likely COVID-19 infections faster than existing tests and requires no contact between the patient and a medical professional, which is an improvement over existing COVID-19 detection technologies.

A breathing monitor that includes a contactless sensor that uses magneto-LC resonance technology is provided. The breathing monitor collects breathing data from a patient that indicates a breathing pattern of the patient. A model trained using machine learning using breathing patterns collected from patients known to have different stages of COVID-19 is used to process the collected breathing data and to determine whether the patient has COVID-19. The model further determines the stage of COVID-19. The breathing monitor can identify likely COVID-19 infections faster than existing tests and requires no contact between the patient and a medical professional, which is an improvement over existing COVID-19 detection technologies.

Disclosed herein are apparatuses for nucleic acid sequencing, and methods of making and using such apparatuses. In some embodiments, the apparatus comprises a magnetic sensor array comprising a plurality of magnetic sensors, each of the plurality of magnetic sensors coupled to at least one address line, and a fluid chamber adjacent to the magnetic sensor array, the fluid chamber having a proximal wall adjacent to the magnetic sensor array. In some embodiments, a method of sequencing nucleic acid using the apparatus comprises (a) coupling a plurality of molecules of a nucleic acid polymerase to the proximal wall of the fluid chamber; (b) in one or more rounds of addition, adding, to the fluid chamber, (i) a nucleic acid template comprising a primer binding site and an extendable primer, and (ii) a first magnetically-labeled nucleotide precursor comprising a first cleavable magnetic label, a second magnetically-labeled nucleotide comprising a second cleavable magnetic label, a third magnetically-labeled nucleotide comprising a third cleavable magnetic label, and a fourth magnetically-labeled nucleotide comprising a fourth cleavable magnetic label; and (c) sequencing the nucleic acid template, wherein sequencing the nucleic acid template comprises, using the at least one address line, detecting a characteristic of at least a portion of the magnetic sensors in the magnetic sensor array, wherein the characteristic indicates which of the first, second, third, or fourth magnetically-labeled nucleotide precursors has been incorporated into the extendable primer. In some embodiments, a method of sequencing nucleic acid using the apparatus comprises (a) binding a nucleic acid strand to the proximal wall; (b) in one or more rounds of addition, adding, to the fluid chamber, (i) an extendable primer, and (ii) a plurality of molecules of a nucleic acid polymerase; (c) adding, to the fluid chamber, a first magnetically-labeled nucleotide precursor comprising a first cleavable magnetic label; and (d) sequencing the nucleic acid template, wherein sequencing the nucleic acid template comprises, using the at least one address line, detecting a characteristic of at least a first portion of the magnetic sensors in the magnetic sensor array, wherein the characteristic indicates that the first magnetically-labeled nucleotide precursor has bound to at least one molecule of the plurality of molecules of the nucleic acid polymerase or has been incorporated into the extendable primer. In some embodiments, a method of manufacturing a nucleic acid sequencing device having at least one fluid chamber configured to contain fluid comprises fabricating a first addressing line on a substrat

Disclosed herein are apparatuses for nucleic acid sequencing, and methods of making and using such apparatuses. In some embodiments, the apparatus comprises a magnetic sensor array comprising a plurality of magnetic sensors, each of the plurality of magnetic sensors coupled to at least one address line, and a fluid chamber adjacent to the magnetic sensor array, the fluid chamber having a proximal wall adjacent to the magnetic sensor array. In some embodiments, a method of sequencing nucleic acid using the apparatus comprises (a) coupling a plurality of molecules of a nucleic acid polymerase to the proximal wall of the fluid chamber; (b) in one or more rounds of addition, adding, to the fluid chamber, (i) a nucleic acid template comprising a primer binding site and an extendable primer, and (ii) a first magnetically-labeled nucleotide precursor comprising a first cleavable magnetic label, a second magnetically-labeled nucleotide comprising a second cleavable magnetic label, a third magnetically-labeled nucleotide comprising a third cleavable magnetic label, and a fourth magnetically-labeled nucleotide comprising a fourth cleavable magnetic label; and (c) sequencing the nucleic acid template, wherein sequencing the nucleic acid template comprises, using the at least one address line, detecting a characteristic of at least a portion of the magnetic sensors in the magnetic sensor array, wherein the characteristic indicates which of the first, second, third, or fourth magnetically-labeled nucleotide precursors has been incorporated into the extendable primer. In some embodiments, a method of sequencing nucleic acid using the apparatus comprises (a) binding a nucleic acid strand to the proximal wall; (b) in one or more rounds of addition, adding, to the fluid chamber, (i) an extendable primer, and (ii) a plurality of molecules of a nucleic acid polymerase; (c) adding, to the fluid chamber, a first magnetically-labeled nucleotide precursor comprising a first cleavable magnetic label; and (d) sequencing the nucleic acid template, wherein sequencing the nucleic acid template comprises, using the at least one address line, detecting a characteristic of at least a first portion of the magnetic sensors in the magnetic sensor array, wherein the characteristic indicates that the first magnetically-labeled nucleotide precursor has bound to at least one molecule of the plurality of molecules of the nucleic acid polymerase or has been incorporated into the extendable primer. In some embodiments, a method of manufacturing a nucleic acid sequencing device having at least one fluid chamber configured to contain fluid comprises fabricating a first addressing line on a substrat

Embodiments of the present disclosure provide novel compositions, methods of use and methods for single composition, multi-dose, thermostable vaccine formulations. In certain embodiments, the present disclosure provides compositions and methods for dehydrating immunogenic agents in the presence of glass-forming agents, and coating the particles formed by the glass-forming agents. In other embodiments, the present disclosure provides for generating compositions for administering an immunogenic composition to a subject multiple times using a single immunogenic composition capable of time-release administration. In other embodiments, single-dose immunogenic agent-containing particles can be directed to two or more pathogens. In other embodiments, incompatible immunogenic agents against two or more different pathogens of immunogenic agent-containing particles disclosed herein can be mixed together and coated for timed-release administration to produce single-administration formulations capable of eliciting an immune response to the two or more pathogens in a subject.